XML 115 R96.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details) - USD ($) $ in Millions | 3 Months Ended |
--- | --- | ---
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2024
Collaborative arrangements and non-collaborative arrangement transactions |  |  |
Share of net profit from sage therapeutics, Percent | 50.00% |  |
Collaboration profit sharing/(loss reimbursement) | $ 65.6 | $ 57.1 |
Sage Therapeutics |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |
Collaboration profit sharing/(loss reimbursement) | 5.0 |  |
Sage Therapeutics | Forecast |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |
Potential future milestone payments commitment to third party |  |  | $ 75.0
Research and development | Sage Therapeutics |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |
Expense incurred by the collaboration | 11.6 | 34.8 |
Expense reflected within statements of income | 5.8 | 17.4 |
Selling, general and administrative | Sage Therapeutics |  |  |
Collaborative arrangements and non-collaborative arrangement transactions |  |  |
Expense incurred by the collaboration | 27.6 | 38.2 |
Expense reflected within statements of income | $ 13.8 | $ 19.1 |

X
- Definition Collaboration profit (loss) sharing + References No definition available. + Details
Name: | biib_Collaborationprofitlosssharing
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expense incurred by the collaboration + References No definition available. + Details
Name: | biib_Expenseincurredbythecollaboration
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expense reflected within statements of income + References No definition available. + Details
Name: | biib_Expensereflectedwithinstatementsofincome
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential future milestone payments commitment to third party approximately. + References No definition available. + Details
Name: | biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Share Of Net Profit From Sage Therapeutics, Percent + References No definition available. + Details
Name: | biib_ShareOfNetProfitFromSageTherapeuticsPercent
Namespace Prefix: | biib_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |